ACADIA PHARMACEUTICALS INC — Director's Dealing 2021

Jan 14, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ACADIA PHARMACEUTICALS INC (ACAD)
CIK: 0001070494
Period of Report: 2021-01-12

Reporting Person: Stankovic Srdjan R. (President)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-01-12	Common Stock	M	700	$18.12	Acquired	20947	Direct
2021-01-12	Common Stock	S	700	$55.01	Disposed	20247	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-01-12	Stock Option (Right to Buy)	$18.12	M	700	Disposed	2028-11-18	Common Stock (700)	Direct

Footnotes

F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 3, 2020.

F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.00 to $55.05 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3: 25% of the shares subject to the Stock Option vested and became exercisable on November 19, 2019. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments.